CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 94 enrolled
Drug / intervention
LY3202626 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02323334
NCT02323334Phase 1Completed
CompareCT.gov

Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626

Eli Lilly and Company·interventional·Posted Dec 23, 2014·Updated Apr 19, 2021

In Brief

A Phase 1 clinical trial evaluating LY3202626, Placebo (Part A, B, C), and 1 other intervention for Healthy Volunteers and Alzheimer Disease. Completed, enrolled 94 participants across 1 site.

Detailed Summary

This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single increasing doses of LY3202626 will be given in capsule form. Part A will also include itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days with the study drug. Part C will last approximately 11-14 weeks. Part D will last approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may only enroll in one part.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Alzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 23, 2014
Enrollment StartDec 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.5 years ago

Interventions

LY3202626drug

administered orally

Placebo (Part A, B, C)drug

administered orally

Itraconazoledrug

administered orally